(Q44011408)

28 November 2017

Phase II Trial of Taxol in Patients with Metastatic Renal Cell Carcinoma (English)

1 reference

https://api.crossref.org/works/10.3109/07357909109044223

26 October 2022

main subject

phase II clinical trial

0 references

1 reference

1 reference

https://api.crossref.org/works/10.3109/07357909109044223

26 October 2022

4

Wiernik PH

1 reference

28 November 2017

A. I. Einzig

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1677827

26 October 2022

E. Gorowski

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1677827

26 October 2022

J. Sasloff

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1677827

26 October 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1677827

26 October 2022

publication date

1 January 1991

1 reference

full work available at URL

28 November 2017

http://www.tandfonline.com/doi/pdf/10.3109/07357909109044223

1 reference

https://api.crossref.org/works/10.3109/07357909109044223

26 October 2022

1 reference

28 November 2017

9

1 reference

28 November 2017

133-136

1 reference

28 November 2017

2

1 reference

Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia

28 November 2017

1 reference

https://api.crossref.org/works/10.3109%2F07357909109044223

Promotion of microtubule assembly in vitro by taxol

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109044223

Taxol stabilizes microtubules in mouse fibroblast cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109044223

Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109044223

Current status of the therapy of advanced renal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109044223

Toxicity and response criteria of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109044223

21 January 2018

4

70

605

Kris M G

1986

1 reference

https://api.crossref.org/works/10.3109/07357909109044223

26 October 2022

5

71

53

Longnecker S M

1987

1 reference

https://api.crossref.org/works/10.3109/07357909109044223

26 October 2022

6

71

1171

Donehower R C

1987

1 reference

https://api.crossref.org/works/10.3109/07357909109044223

26 October 2022

7

71

1179

Grem J L

1987

1 reference

https://api.crossref.org/works/10.3109/07357909109044223

Proceedings of the American Association for Cancer Research

26 October 2022

9

26

167

Ohnuma T

1985

1 reference

https://api.crossref.org/works/10.3109/07357909109044223

Phase I study of taxol using a 5-day intermittent schedule

26 October 2022

10

1 reference

https://api.crossref.org/works/10.3109/07357909109044223

Proceedings: Chemotherapy of adenocarcinoma of the kidney

26 October 2022

13

1 reference

https://api.crossref.org/works/10.3109/07357909109044223

The current status of chemotherapy for advanced renal carcinoma.

26 October 2022

14

1 reference

https://api.crossref.org/works/10.3109/07357909109044223

Current Therapy for Renal Cell Carcinoma

26 October 2022

15

1 reference

https://api.crossref.org/works/10.3109/07357909109044223

26 October 2022

Identifiers

1 reference

28 November 2017

1 reference